MB-104 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize SLAMF7/CS-1 (a protein found on myeloma cells) more easily.
| SparkCures ID | 334 |
|---|---|
| Generic Name | MB-104 |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.